Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by...

Full description

Bibliographic Details
Main Authors: Soo Young Kim, Seok-Mo Kim, Jun Won Kim, Ik Jae Lee, Tae Joo Jeon, Hojin Chang, Bup-Woo Kim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Endocrinology
Subjects:
lenvatinib
thyroid carcinoma
anaplastic thyroid cancer
retrospective study
tyrosine kinase inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2020.00599/full

Similar Items

Similar Items